D
Fate Therapeutics, Inc.
FATE
$0.9205
-$0.0458-4.74%
D
Sell
3/6/2025Upgraded
Fate Therapeutics, Inc. (FATE) was upgraded to D- from E+ on 3/6/2025 due to an increase in the volatility index.
Fate Therapeutics, Inc. (FATE) was upgraded to D- from E+ on 3/6/2025 due to an increase in the volatility index.
E
Sell
3/5/2025Downgrade
Fate Therapeutics, Inc. (FATE) was downgraded to E+ from D- on 3/5/2025 due to a decline in the total return index and volatility index.
Fate Therapeutics, Inc. (FATE) was downgraded to E+ from D- on 3/5/2025 due to a decline in the total return index and volatility index.
D
Sell
2/18/2025Upgraded
Fate Therapeutics, Inc. (FATE) was upgraded to D- from E+ on 2/18/2025 due to an increase in the valuation index and solvency index.
Fate Therapeutics, Inc. (FATE) was upgraded to D- from E+ on 2/18/2025 due to an increase in the valuation index and solvency index.
E
Sell
8/1/2024Downgrade
Fate Therapeutics, Inc. (FATE) was downgraded to E+ from D- on 8/1/2024 due to a decline in the growth index, total return index and valuation index.
Fate Therapeutics, Inc. (FATE) was downgraded to E+ from D- on 8/1/2024 due to a decline in the growth index, total return index and valuation index.
D
Sell
7/16/2024Upgraded
Fate Therapeutics, Inc. (FATE) was upgraded to D- from E+ on 7/16/2024 due to an increase in the volatility index.
Fate Therapeutics, Inc. (FATE) was upgraded to D- from E+ on 7/16/2024 due to an increase in the volatility index.
E
Sell
6/28/2024Downgrade
Fate Therapeutics, Inc. (FATE) was downgraded to E+ from D- on 6/28/2024 due to a major decline in the growth index and volatility index. EBIT declined 45.18% from -$35.18M to -$51.07M, and earnings per share declined from -$0.4522 to -$0.4748.
Fate Therapeutics, Inc. (FATE) was downgraded to E+ from D- on 6/28/2024 due to a major decline in the growth index and volatility index. EBIT declined 45.18% from -$35.18M to -$51.07M, and earnings per share declined from -$0.4522 to -$0.4748.
D
Sell
2/15/2024Upgraded
Fate Therapeutics, Inc. (FATE) was upgraded to D- from E+ on 2/15/2024 due to a large increase in the growth index and volatility index. Total revenue increased 108.36% from $933 to $1.94M, EBIT increased 18.04% from -$62.57M to -$51.28M, and earnings per share increased from -$0.5361 to -$0.4583.
Fate Therapeutics, Inc. (FATE) was upgraded to D- from E+ on 2/15/2024 due to a large increase in the growth index and volatility index. Total revenue increased 108.36% from $933 to $1.94M, EBIT increased 18.04% from -$62.57M to -$51.28M, and earnings per share increased from -$0.5361 to -$0.4583.
E
Sell
3/14/2023Downgrade
Fate Therapeutics, Inc. (FATE) was downgraded to E+ from D on 3/14/2023 due to a decline in the solvency index, total return index and volatility index. The quick ratio declined from 4.97 to 4.17.
Fate Therapeutics, Inc. (FATE) was downgraded to E+ from D on 3/14/2023 due to a decline in the solvency index, total return index and volatility index. The quick ratio declined from 4.97 to 4.17.
D
Sell
2/23/2023Upgraded
Fate Therapeutics, Inc. (FATE) was upgraded to D from D- on 02/23/2023.
Fate Therapeutics, Inc. (FATE) was upgraded to D from D- on 02/23/2023.
D
Sell
2/8/2023Downgrade
Fate Therapeutics, Inc. (FATE) was downgraded to D- from D on 2/8/2023 due to a major decline in the total return index, growth index and volatility index. Total revenue declined 19.24% from $18.55M to $14.98M, earnings per share declined from -$0.787 to -$0.8613, and EBIT declined 3.95% from -$83.11M to -$86.39M.
Fate Therapeutics, Inc. (FATE) was downgraded to D- from D on 2/8/2023 due to a major decline in the total return index, growth index and volatility index. Total revenue declined 19.24% from $18.55M to $14.98M, earnings per share declined from -$0.787 to -$0.8613, and EBIT declined 3.95% from -$83.11M to -$86.39M.
D
Sell
5/5/2022Upgraded
Fate Therapeutics, Inc. (FATE) was upgraded to D from D- on 5/5/2022 due to an increase in the growth index and valuation index. Operating cash flow increased 8.08% from -$70.29M to -$64.61M, total revenue increased 7.88% from $17.07M to $18.41M, and earnings per share increased from -$0.7164 to -$0.6818.
Fate Therapeutics, Inc. (FATE) was upgraded to D from D- on 5/5/2022 due to an increase in the growth index and valuation index. Operating cash flow increased 8.08% from -$70.29M to -$64.61M, total revenue increased 7.88% from $17.07M to $18.41M, and earnings per share increased from -$0.7164 to -$0.6818.
D
Sell
4/20/2022Downgrade
Fate Therapeutics, Inc. (FATE) was downgraded to D- from D on 4/20/2022 due to a decline in the growth index, total return index and volatility index. Operating cash flow declined 110.62% from -$33.38M to -$70.29M, earnings per share declined from -$0.4539 to -$0.7164, and EBIT declined 27.02% from -$54.62M to -$69.38M.
Fate Therapeutics, Inc. (FATE) was downgraded to D- from D on 4/20/2022 due to a decline in the growth index, total return index and volatility index. Operating cash flow declined 110.62% from -$33.38M to -$70.29M, earnings per share declined from -$0.4539 to -$0.7164, and EBIT declined 27.02% from -$54.62M to -$69.38M.
D
Sell
11/23/2021Upgraded
Fate Therapeutics, Inc. (FATE) was upgraded to D from D- on 11/23/2021 due to an increase in the valuation index.
Fate Therapeutics, Inc. (FATE) was upgraded to D from D- on 11/23/2021 due to an increase in the valuation index.
D
Sell
11/8/2021Downgrade
Fate Therapeutics, Inc. (FATE) was downgraded to D- from D on 11/8/2021 due to a decline in the volatility index and total return index.
Fate Therapeutics, Inc. (FATE) was downgraded to D- from D on 11/8/2021 due to a decline in the volatility index and total return index.
D
Sell
4/20/2021Downgrade
Fate Therapeutics, Inc. (FATE) was downgraded to D from D+ on 4/20/2021 due to a major decline in the total return index, growth index and solvency index. The quick ratio declined from 9.08 to 5.71, and EBIT declined 6.07% from -$31.49M to -$33.4M.
Fate Therapeutics, Inc. (FATE) was downgraded to D from D+ on 4/20/2021 due to a major decline in the total return index, growth index and solvency index. The quick ratio declined from 9.08 to 5.71, and EBIT declined 6.07% from -$31.49M to -$33.4M.
D
Sell
10/22/2020Upgraded
Fate Therapeutics, Inc. (FATE) was upgraded to D+ from D on 10/22/2020 due to a major increase in the total return index, growth index and volatility index. Operating cash flow increased 245.62% from -$26.67M to $38.84M, total revenue increased 117.3% from $2.52M to $5.47M, and earnings per share increased from -$0.4417 to -$0.354.
Fate Therapeutics, Inc. (FATE) was upgraded to D+ from D on 10/22/2020 due to a major increase in the total return index, growth index and volatility index. Operating cash flow increased 245.62% from -$26.67M to $38.84M, total revenue increased 117.3% from $2.52M to $5.47M, and earnings per share increased from -$0.4417 to -$0.354.
D
Sell
11/6/2019Upgraded
Fate Therapeutics, Inc. (FATE) was upgraded to D from D- on 11/6/2019 due to an increase in the efficiency index, solvency index and valuation index. Total capital increased 81.81% from $170.11M to $309.28M, debt to equity declined from 0.13 to 0.06, and the quick ratio increased from 5.51 to 7.46.
Fate Therapeutics, Inc. (FATE) was upgraded to D from D- on 11/6/2019 due to an increase in the efficiency index, solvency index and valuation index. Total capital increased 81.81% from $170.11M to $309.28M, debt to equity declined from 0.13 to 0.06, and the quick ratio increased from 5.51 to 7.46.
D
Sell
10/9/2019Downgrade
Fate Therapeutics, Inc. (FATE) was downgraded to D- from D on 10/9/2019 due to a significant decline in the total return index, solvency index and efficiency index. Net income declined 18.82% from -$19.76M to -$23.48M, debt to equity increased from 0.11 to 0.13, and the quick ratio declined from 6.3 to 5.51.
Fate Therapeutics, Inc. (FATE) was downgraded to D- from D on 10/9/2019 due to a significant decline in the total return index, solvency index and efficiency index. Net income declined 18.82% from -$19.76M to -$23.48M, debt to equity increased from 0.11 to 0.13, and the quick ratio declined from 6.3 to 5.51.
D
Sell
11/6/2018Upgraded
Fate Therapeutics, Inc. (FATE) was upgraded to D from D- on 11/6/2018 due to a significant increase in the total return index, solvency index and volatility index. The quick ratio increased from 4.79 to 9.34, and debt to equity declined from 0.29 to 0.09.
Fate Therapeutics, Inc. (FATE) was upgraded to D from D- on 11/6/2018 due to a significant increase in the total return index, solvency index and volatility index. The quick ratio increased from 4.79 to 9.34, and debt to equity declined from 0.29 to 0.09.
D
Sell
6/28/2017Downgrade
Fate Therapeutics, Inc. (FATE) was downgraded to D- from D on 6/28/2017 due to a decline in the total return index and volatility index.
Fate Therapeutics, Inc. (FATE) was downgraded to D- from D on 6/28/2017 due to a decline in the total return index and volatility index.
D
Sell
6/8/2017Upgraded
Fate Therapeutics, Inc. (FATE) was upgraded to D from D- on 6/8/2017 due to an increase in the valuation index.
Fate Therapeutics, Inc. (FATE) was upgraded to D from D- on 6/8/2017 due to an increase in the valuation index.
D
Sell
5/23/2017Downgrade
Fate Therapeutics, Inc. (FATE) was downgraded to D- from D on 5/23/2017 due to a noticeable decline in the growth index, solvency index and efficiency index. EBIT declined 30.27% from -$7.65M to -$9.97M, net income declined 27.53% from -$7.94M to -$10.13M, and the quick ratio declined from 6.07 to 4.87.
Fate Therapeutics, Inc. (FATE) was downgraded to D- from D on 5/23/2017 due to a noticeable decline in the growth index, solvency index and efficiency index. EBIT declined 30.27% from -$7.65M to -$9.97M, net income declined 27.53% from -$7.94M to -$10.13M, and the quick ratio declined from 6.07 to 4.87.
D
Sell
3/21/2017Upgraded
Fate Therapeutics, Inc. (FATE) was upgraded to D from D- on 3/21/2017 due to a significant increase in the total return index, growth index and volatility index. Earnings per share increased from -$0.2723 to -$0.2133, EBIT increased 8.76% from -$8.39M to -$7.65M, and total revenue increased 0.1% from $1.03M to $1.03M.
Fate Therapeutics, Inc. (FATE) was upgraded to D from D- on 3/21/2017 due to a significant increase in the total return index, growth index and volatility index. Earnings per share increased from -$0.2723 to -$0.2133, EBIT increased 8.76% from -$8.39M to -$7.65M, and total revenue increased 0.1% from $1.03M to $1.03M.
D
Sell
3/11/2016Downgrade
Fate Therapeutics, Inc. (FATE) was downgraded to D- from D on 3/11/2016 due to a large decline in the volatility index, total return index and efficiency index. Total capital declined 12.24% from $64.12M to $56.28M, and net income declined 8.13% from -$6.89M to -$7.45M.
Fate Therapeutics, Inc. (FATE) was downgraded to D- from D on 3/11/2016 due to a large decline in the volatility index, total return index and efficiency index. Total capital declined 12.24% from $64.12M to $56.28M, and net income declined 8.13% from -$6.89M to -$7.45M.
D
Sell
11/3/2014Upgraded
Fate Therapeutics, Inc. (FATE) was upgraded to D from D- on 11/3/2014 due to an increase in the growth index and efficiency index. Operating cash flow increased 4.45% from -$5.26M to -$5.49M.
Fate Therapeutics, Inc. (FATE) was upgraded to D from D- on 11/3/2014 due to an increase in the growth index and efficiency index. Operating cash flow increased 4.45% from -$5.26M to -$5.49M.
D
Sell
7/1/2014Upgraded
Fate Therapeutics, Inc. (FATE) was upgraded to D- from E+ on 7/1/2014 due to an increase in the valuation index.
Fate Therapeutics, Inc. (FATE) was upgraded to D- from E+ on 7/1/2014 due to an increase in the valuation index.
E
Sell
4/1/2014Upgraded
Fate Therapeutics, Inc. (FATE) was upgraded to E+ from E on 4/1/2014 due to a significant increase in the solvency index, volatility index and total return index. The quick ratio increased from 2.01 to 11.75, and debt to equity declined from -0.39 to 0.03.
Fate Therapeutics, Inc. (FATE) was upgraded to E+ from E on 4/1/2014 due to a significant increase in the solvency index, volatility index and total return index. The quick ratio increased from 2.01 to 11.75, and debt to equity declined from -0.39 to 0.03.
NASDAQ
03/18/2025 4:00PM Eastern
Quotes delayed
